TY - JOUR
T1 - 11,11′-Dideoxy-verticillin
T2 - A natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity
AU - Zhang, Yi Xiang
AU - Chen, Yi
AU - Guo, Xiao Ning
AU - Zhang, Xiong Wen
AU - Zhao, Wei Min
AU - Zhong, Li
AU - Zhou, Jin
AU - Xi, Yong
AU - Lin, Li Ping
AU - Ding, Jian
PY - 2005/5
Y1 - 2005/5
N2 - 11,11′-Dideoxy-verticillin, a compound of the novel epidithiodioxopiprazine structural class, is isolated from the traditional Chinese medicinal herb Shiraia bambusicola. The present study demonstrated for the first time that 11,11′-dideoxy-verticillin has potent tyrosine kinase-inhibitory and anti-tumor activities. In the cell-free ELISA tyrosine kinase assay, 11,11′-dideoxy-verticillin significantly inhibited the activities of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor-1/fms-like tyrosine kinase-1 (VEGFR-1/Flt-1) and human epidermal growth factor receptor-2 (HER2/ErbB-2), with relative specificity on EGFR and VEGFR-1 with IC50S of 0.136±0.109 and 1.645±0.885 nM, respectively. Exposure of 11,11′-dideoxy- verticillin for 1 h to EGFR-overexpressed MDA-MB-468 human breast carcinoma cells and HER2-overexpressed SK-OV-3 human ovarian adenocarcinoma cells resulted in obvious inhibition of EGF-induced phosphorylation of EGFR and HER2. In addition, 11,11′-dideoxy-verticillin also inhibited the EGF-induced phosphorylation of Erk1/2, but had no effect on the phosphorylation of AKT in both tumor cell lines. Moreover, 11,11′-dideoxy-verticillin has potent anti-tumor activity. In vitro cytotoxicity assay showed that 11,11′-dideoxy-verticillin potently inhibited the proliferation of four human breast tumor cell lines with an average IC50 value of 0.2 μM. In vivo, 11,11′-dideoxy-verticillin exhibited remarkable efficacy against mice sarcoma 180 and hepatoma 22 after daily i.p. administration of 0.5 or 0.75 mg/kg with inhibition rates ranging from 45.0 to 72.4%. Treated with 11,11′-dideoxy-verticillin at 0.5-2.0 μM for 36 h, MB-MB-468 cells exhibited significant apoptotic morphological changes. At low concentrations (0.0625-0.5 μM) for 24 h, 11,11′-dideoxy-verticillin induced a dose-dependent accumulation of MDA-MB-468 cells in the G2/M phase of the cell cycle. These results indicate that 11,11′-dideoxy-verticillin is a naturally derived growth factor receptor tyrosine kinase inhibitor with potent anti-tumor activity.
AB - 11,11′-Dideoxy-verticillin, a compound of the novel epidithiodioxopiprazine structural class, is isolated from the traditional Chinese medicinal herb Shiraia bambusicola. The present study demonstrated for the first time that 11,11′-dideoxy-verticillin has potent tyrosine kinase-inhibitory and anti-tumor activities. In the cell-free ELISA tyrosine kinase assay, 11,11′-dideoxy-verticillin significantly inhibited the activities of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor-1/fms-like tyrosine kinase-1 (VEGFR-1/Flt-1) and human epidermal growth factor receptor-2 (HER2/ErbB-2), with relative specificity on EGFR and VEGFR-1 with IC50S of 0.136±0.109 and 1.645±0.885 nM, respectively. Exposure of 11,11′-dideoxy- verticillin for 1 h to EGFR-overexpressed MDA-MB-468 human breast carcinoma cells and HER2-overexpressed SK-OV-3 human ovarian adenocarcinoma cells resulted in obvious inhibition of EGF-induced phosphorylation of EGFR and HER2. In addition, 11,11′-dideoxy-verticillin also inhibited the EGF-induced phosphorylation of Erk1/2, but had no effect on the phosphorylation of AKT in both tumor cell lines. Moreover, 11,11′-dideoxy-verticillin has potent anti-tumor activity. In vitro cytotoxicity assay showed that 11,11′-dideoxy-verticillin potently inhibited the proliferation of four human breast tumor cell lines with an average IC50 value of 0.2 μM. In vivo, 11,11′-dideoxy-verticillin exhibited remarkable efficacy against mice sarcoma 180 and hepatoma 22 after daily i.p. administration of 0.5 or 0.75 mg/kg with inhibition rates ranging from 45.0 to 72.4%. Treated with 11,11′-dideoxy-verticillin at 0.5-2.0 μM for 36 h, MB-MB-468 cells exhibited significant apoptotic morphological changes. At low concentrations (0.0625-0.5 μM) for 24 h, 11,11′-dideoxy-verticillin induced a dose-dependent accumulation of MDA-MB-468 cells in the G2/M phase of the cell cycle. These results indicate that 11,11′-dideoxy-verticillin is a naturally derived growth factor receptor tyrosine kinase inhibitor with potent anti-tumor activity.
KW - 11,11′-dideoxy-verticillin
KW - Anti-tumor
KW - Epidermal growth factor receptor
KW - Erk1/2
KW - Vascular endothelial growth factor receptor-1
UR - https://www.scopus.com/pages/publications/21044436266
U2 - 10.1097/00001813-200506000-00007
DO - 10.1097/00001813-200506000-00007
M3 - 文章
C2 - 15846117
AN - SCOPUS:21044436266
SN - 0959-4973
VL - 16
SP - 515
EP - 524
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
IS - 5
ER -